<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-449" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Epithelioid Sarcoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Needs</surname>
            <given-names>Todd</given-names>
          </name>
          <aff>San Antonio Military Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fillman</surname>
            <given-names>Eric P.</given-names>
          </name>
          <aff>San Antonio Military Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Todd Needs declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Eric Fillman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-449.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Epithelioid sarcoma is a rare and aggressive soft tissue sarcoma characterized by both epithelial and mesenchymal differentiation. This condition most commonly affects young adults and typically presents as a painless and slow-growing mass, which is often located in the distal extremities. Despite its slow growth, epithelioid sarcoma is highly aggressive, posing a significant risk of recurrence, lymph node involvement, and distant metastases. Diagnosis is typically made through tissue biopsy, while imaging studies are essential for assessing the extent of the primary tumor and identifying metastatic disease. Microscopically, the conventional form exhibits a nodular or lobular architecture with central necrosis and surrounding epithelioid cells, while the proximal-type variant is characterized by more cytologic pleomorphism and nuclear atypia.</p>
        <p>The primary treatment for epithelioid sarcoma is complete surgical removal, which is curative in the early stages. Radiation therapy may be used as an adjunct to reduce recurrence risk, and more recently, targeted therapies have been developed for advanced cases. Due to the high likelihood of late metastases, long-term monitoring&#x000a0;is essential for managing the disease.&#x000a0;This activity reviews the etiology, histopathology, evaluation, and management of epithelioid sarcoma. This activity also helps healthcare providers identify, diagnose, and manage epithelioid sarcoma, ensuring timely and accurate treatment and improving patient outcomes through early interprofessional collaboration.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify early clinical signs and symptoms suggestive of epithelioid sarcoma.</p></list-item><list-item><p>Screen high-risk populations, such as young adults with painless, slow-growing masses in distal extremities, for epithelioid sarcoma.</p></list-item><list-item><p>Select appropriate adjuvant therapies, such as radiation therapy or targeted therapies, based on tumor characteristics and patient factors.</p></list-item><list-item><p>Collaborate with multidisciplinary healthcare teams, including surgeons, oncologists, radiologists, and pathologists, to optimize treatment strategies and care for&#x000a0;patients with epithelioid sarcoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=449&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=449">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-449.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Epithelioid sarcoma is a rare and aggressive soft tissue sarcoma characterized by both epithelial and mesenchymal differentiation. This condition most commonly affects young adults and typically presents as a painless and slow-growing mass often located in the distal extremities.<xref ref-type="bibr" rid="article-449.r1">[1]</xref> Epithelioid sarcoma is locally invasive and frequently metastasizes to regional lymph nodes and distant sites. Diagnosis is determined by tissue biopsy, while imaging studies are essential for assessing the extent of the primary tumor and identifying metastatic disease.</p>
        <p>Complete surgical resection is curative in early-stage disease. However, local recurrence and late distant metastases may occur, necessitating long-term surveillance.<xref ref-type="bibr" rid="article-449.r2">[2]</xref>&#x000a0;Radiation therapy may be used as an adjunct treatment and as a palliative measure. Recently, treatment options have evolved with the development of targeted therapies, which aim to improve patient outcomes.</p>
      </sec>
      <sec id="article-449.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Epithelioid sarcomas are malignant tumors with both mesenchymal and epithelial cell differentiation. Up to 90% of epithelioid sarcomas show loss of integrase interactor-1 (<italic toggle="yes">INI-1</italic>) expression.<xref ref-type="bibr" rid="article-449.r3">[3]</xref>&#x000a0;<italic toggle="yes">INI-1</italic> is part of the <italic toggle="yes">SWI/SNF</italic> chromatin remodeling complex, which is expressed in all normal nucleated cells. This chromatin remodeling complex is essential for biological function as it alters nucleosomes to allow for DNA transcription.</p>
        <p><italic toggle="yes">INI-1</italic>, or <italic toggle="yes">SMARCB1</italic>, is located on chromosome 22 at the 22q11 band.&#x000a0;A spectrum of gene deletions and rearrangements, including translocation events involving the 22q11 locus, are responsible for tumorigenesis in<italic toggle="yes"> INI-1&#x02013;</italic>deficient epithelioid sarcomas.<xref ref-type="bibr" rid="article-449.r4">[4]</xref>&#x000a0;Intriguingly, an association with prior trauma at the site of the tumor has been noted in up to 27% of occurrences.<xref ref-type="bibr" rid="article-449.r5">[5]</xref>&#x000a0;However, previous trauma to the distal extremity is logically a common occurrence, making it difficult to definitively speculate on its role as an inciting event.</p>
      </sec>
      <sec id="article-449.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Epithelioid sarcomas are rare, accounting for less than 1% of soft tissue sarcomas.<xref ref-type="bibr" rid="article-449.r2">[2]</xref>&#x000a0;They predominantly affect men, with a male-to-female ratio of up to 2:1.<xref ref-type="bibr" rid="article-449.r6">[6]</xref> Most reported tumors occur in young males aged 10 to 45.<xref ref-type="bibr" rid="article-449.r2">[2]</xref><xref ref-type="bibr" rid="article-449.r5">[5]</xref><xref ref-type="bibr" rid="article-449.r1">[1]</xref><xref ref-type="bibr" rid="article-449.r7">[7]</xref>&#x000a0;The age range spans from 4 to 90, with a median age of 27.<xref ref-type="bibr" rid="article-449.r6">[6]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-449.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histologically, the conventional or usual type of epithelioid sarcoma exhibits a nodular or lobular architecture with central areas of necrosis surrounded by polygonal epithelioid cells characterized by relatively abundant eosinophilic cytoplasm. This appearance under low-power microscopy resembles a granulomatous lesion. Nuclear atypia is minimal, and mitotic figures are typically absent.<xref ref-type="bibr" rid="article-449.r1">[1]</xref><xref ref-type="bibr" rid="article-449.r5">[5]</xref>&#x000a0;Tumor cells at the periphery often exhibit a spindled or sarcomatous appearance. Various histological patterns further complicate the diagnosis, as some tumors may resemble angiomatoid or fibromatoid lesions.<xref ref-type="bibr" rid="article-449.r6">[6]</xref><xref ref-type="bibr" rid="article-449.r8">[8]</xref>&#x000a0;These&#x000a0;features can lead the pathologist to consider differential diagnoses, including vascular neoplasms, benign processes such as fibromatosis, or even reactive lesions such as nodular fasciitis.</p>
        <p>The proximal-type variant of epithelioid sarcoma lacks the granulomatous pattern of necrosis (see <bold>Image</bold>.&#x000a0;Epithelioid Sarcoma, Proximal-Type). Instead, the tumor is characterized by cellular nodules exhibiting increased cytologic pleomorphism, nuclear atypia, and sometimes signet-ring-like vacuolation.<xref ref-type="bibr" rid="article-449.r5">[5]</xref><xref ref-type="bibr" rid="article-449.r7">[7]</xref>&#x000a0;Rhabdoid morphology with prominent nucleoli is characteristic of this lesion. Although the proximal type is typically found near the trunk, proximal variants of epithelioid sarcoma are defined by histological features, not location.<xref ref-type="bibr" rid="article-449.r2">[2]</xref><xref ref-type="bibr" rid="article-449.r9">[9]</xref>&#x000a0;Furthermore, the usual proximal location of this variant increases diagnostic challenges due to overlapping features with metastatic carcinoma, which often occur in proximal sites such as the groin and pelvic area.<xref ref-type="bibr" rid="article-449.r7">[7]</xref></p>
        <p>The immunohistochemical profile of epithelioid sarcoma typically shows strong expression of cytokeratins, epithelial membrane antigen (EMA), and vimentin, and often CD34 positivity, which is relatively unique. The most crucial diagnostic finding is the absence of <italic toggle="yes">INI-1</italic> expression in tumor cells.&#x000a0;Additionally, as discussed further in the Differential Diagnosis section below, is the typically negative immunolabeling of the tumor cells for S100, desmin, and CD31.<xref ref-type="bibr" rid="article-449.r5">[5]</xref><xref ref-type="bibr" rid="article-449.r3">[3]</xref><xref ref-type="bibr" rid="article-449.r6">[6]</xref><xref ref-type="bibr" rid="article-449.r10">[10]</xref></p>
        <p>
<bold>Immunohistochemical Profile Summary</bold>
</p>
        <p>Positive labeling<bold>&#x000a0;</bold>includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cytokeratin</p>
          </list-item>
          <list-item>
            <p>EMA</p>
          </list-item>
          <list-item>
            <p>Vimentin</p>
          </list-item>
          <list-item>
            <p>CD 34 (approximately 50% of cases)&#x000a0;<xref ref-type="bibr" rid="article-449.r5">[5]</xref><xref ref-type="bibr" rid="article-449.r3">[3]</xref><xref ref-type="bibr" rid="article-449.r6">[6]</xref><xref ref-type="bibr" rid="article-449.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>Negative labeling includes:</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">INI-1</italic>/<italic toggle="yes">SMARCB1</italic>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>S100</p>
          </list-item>
          <list-item>
            <p>Desmin</p>
          </list-item>
          <list-item>
            <p>Factor VIII-related antigen</p>
          </list-item>
          <list-item>
            <p>Cytokeratin 7</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-449.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Epithelioid sarcoma presents as a slow-growing, nodular lesion, most commonly involving the distal upper extremity, particularly the fingers, hands, and forearm. Lesions are usually painless and enlarge slowly, developing a multinodular appearance. Ulceration of the overlying skin and invasion of surrounding structures are common.<xref ref-type="bibr" rid="article-449.r2">[2]</xref><xref ref-type="bibr" rid="article-449.r5">[5]</xref><xref ref-type="bibr" rid="article-449.r6">[6]</xref>&#x000a0;The lesion can arise in the dermis, subcutis, or deep fascia. Notably, obtaining a history of the lesion's onset, growth rate, any antecedent trauma, neurovascular deficit symptoms, and symptoms of pulmonary metastatic disease (eg, new onset of cough or hematemesis) is important.&#x000a0;</p>
        <p>Epithelioid sarcoma characteristically invades along fascial planes and tracks along tendons and aponeuroses, leading to a significantly wider area of involvement than is clinically visible.<xref ref-type="bibr" rid="article-449.r2">[2]</xref> The proximal variant of epithelioid sarcoma occurs more often in the perineal, pubic, genital, and truncal regions.<xref ref-type="bibr" rid="article-449.r2">[2]</xref><xref ref-type="bibr" rid="article-449.r7">[7]</xref>&#x000a0;Masses can be large, up to 20 cm, especially in the proximal variant, but are often less than 5 cm in greatest dimension.<xref ref-type="bibr" rid="article-449.r1">[1]</xref><xref ref-type="bibr" rid="article-449.r5">[5]</xref><xref ref-type="bibr" rid="article-449.r6">[6]</xref>&#x000a0;</p>
        <p>A physical exam should focus on the size of the tumor, its relation to surrounding structures, invasion into surrounding structures, and any overlying skin changes. As epithelioid sarcoma has a high rate of lymph node metastases, which is unusual for soft tissue sarcomas, all draining lymph node basins should be examined.<xref ref-type="bibr" rid="article-449.r2">[2]</xref>&#x000a0;A general physical evaluation, including a whole-body skin examination, pulmonary auscultation, and assessment of other potential sites of metastatic disease, is critical.&#x000a0;</p>
      </sec>
      <sec id="article-449.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A tissue biopsy is necessary, as soft tissue swellings have many possible causes. Core needle biopsies are the preferred method. Based on clinical examination, biopsies should also be taken from any suspicious lymph nodes. Magnetic resonance imaging (MRI) is the preferred diagnostic tool for most soft-tissue sarcomas, as it provides detailed images of the extent of tumor invasion into the surrounding fascial planes. An image-guided biopsy may be preferred for larger lesions with significant necrotic components, enabling targeted biopsies from more metabolically active areas. In some cases, incisional or excisional biopsies may be necessary. When surgical biopsies are performed, they should be oriented to incorporate them into any future surgical excision.</p>
        <p>Epithelioid sarcoma is associated with a high rate of distant metastases, with recent studies suggesting a distant metastasis rate of up to 50%. The most common sites of metastases are the lungs, lymph nodes, and skin. As a result, staging imaging with a chest computed tomography (CT) scan is typically performed. For more extensive staging, fluorodeoxyglucose-positron emission tomography (FDG-PET) scans or additional CT scans may be necessary, depending on the characteristics of the primary tumor.<xref ref-type="bibr" rid="article-449.r11">[11]</xref></p>
      </sec>
      <sec id="article-449.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Wide excision is the treatment of choice for nonmetastatic epithelioid sarcoma. Although margins of 2 to 5 cm have been described, the extent of resection should be individualized, with every effort made to preserve limb function. Despite its propensity for metastasis, sentinel lymph node biopsy is not recommended in clinically node-negative patients. Lymph node dissection of the involved basin is indicated in patients with clinically positive lymph nodes. The surgical management of solitary in-transit metastases and isolated pulmonary metastases is controversial, and the lack of randomized clinical trials affects the available data. Metastasectomy may be indicated in certain situations.&#x000a0;</p>
        <p>Radiation therapy is often added to mitigate local recurrence; however, the indications for radiation therapy are relatively undefined.<xref ref-type="bibr" rid="article-449.r12">[12]</xref>&#x000a0;Current indications for radiation therapy include patients with narrow margins, microscopically positive margins, local recurrence, and use as a palliative modality in patients with large tumors.<xref ref-type="bibr" rid="article-449.r13">[13]</xref> More recently, an inhibitor of enhancer of zeste homolog 2 (EZH2), Tazemetostat, has been approved for patients with unresectable or metastatic epithelioid sarcoma.<xref ref-type="bibr" rid="article-449.r14">[14]</xref>&#x000a0;</p>
        <p>Local recurrence rates of 40% to 60% have been reported, with a median time to recurrence of 1 to 2 years. However, recurrences have been reported as late as 20 years after the initial operation. As a result, close surveillance with cross-sectional imaging of the primary site and lungs is critical, typically with imaging studies every 6 months to 1 year.<xref ref-type="bibr" rid="article-449.r15">[15]</xref></p>
      </sec>
      <sec id="article-449.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Diagnosing epithelioid sarcoma can be challenging due to its mixed mesenchymal and epithelial differentiation. This unique characteristic can cause the tumor to appear similar to various other reactive, benign, and malignant processes, making histologic diagnosis alone difficult. Immunohistochemical labeling may be used to confirm the diagnosis, although it is essential to consider other more common diagnostic entities with similar histologic and immunophenotypic characteristics. The most accurate diagnosis can be made by considering the appropriate clinical context, such as the presence of a soft tissue mass on the extremity of a young male, with immunohistochemical staining providing diagnostic support.</p>
        <p>The differential diagnosis based on histomorphology generally includes reactive and benign lesions such as granulomatous diseases, nodular fasciitis, fibrohistiocytic lesions, fibromatosis, and tenosynovial giant cell tumors. Malignant lesions in the differential diagnosis include metastatic carcinoma, melanoma, synovial sarcoma, vascular neoplasms, spindle cell squamous cell carcinoma, malignant peripheral nerve sheath tumor (MPNST), and extrarenal rhabdoid tumor.<xref ref-type="bibr" rid="article-449.r1">[1]</xref><xref ref-type="bibr" rid="article-449.r5">[5]</xref><xref ref-type="bibr" rid="article-449.r3">[3]</xref><xref ref-type="bibr" rid="article-449.r6">[6]</xref></p>
        <p>The following is a summary of immunohistochemical stains for epithelioid sarcoma:</p>
        <list list-type="bullet">
          <list-item>
            <p>CD34: Positive in half of epithelioid sarcoma (negative in synovial sarcoma and most carcinomas).</p>
          </list-item>
          <list-item>
            <p>Vimentin: Positive in epithelioid sarcoma (negative in many carcinomas, except notably endometrial and renal).</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">INI-1</italic>: Complete loss is distinctive.</p>
          </list-item>
          <list-item>
            <p>CK7: Negative in epithelioid sarcoma (positive in synovial sarcoma).</p>
          </list-item>
          <list-item>
            <p>CK5/6 and p63: Negative in epithelioid sarcoma (positive in squamous cell carcinoma).</p>
          </list-item>
          <list-item>
            <p>S100: Negative in epithelioid sarcoma (positive in MPNST and many melanomas).</p>
          </list-item>
          <list-item>
            <p>CD31: Negative in epithelioid sarcoma, except in 1 documented case (positive in vascular lesions).<xref ref-type="bibr" rid="article-449.r16">[16]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>SALL4: Negative in 89% of epithelioid sarcoma (positive in 71% of malignant rhabdoid tumors).<xref ref-type="bibr" rid="article-449.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>ERG: Variably positive in epithelioid sarcoma (negative in all malignant rhabdoid tumors).<xref ref-type="bibr" rid="article-449.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Vascular markers: ERG, FLI1, and D240 have been demonstrated in epithelioid sarcoma.<xref ref-type="bibr" rid="article-449.r8">[8]</xref><xref ref-type="bibr" rid="article-449.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-449.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis, as with most malignancies, is primarily determined by the clinical stage of the disease. Epithelioid sarcoma prognosis is most closely associated with tumor size, vascular invasion, resectability,&#x000a0;and metastases.<xref ref-type="bibr" rid="article-449.r6">[6]</xref>&#x000a0;Large tumor size and early metastases are independently associated with poor outcomes.<xref ref-type="bibr" rid="article-449.r9">[9]</xref>&#x000a0;The proximal type is generally described as a more aggressive tumor; however, at least one study&#x000a0;demonstrated no significant difference in overall survival between the proximal and usual types of epithelioid sarcoma.<xref ref-type="bibr" rid="article-449.r2">[2]</xref></p>
        <p>Gender, age at diagnosis, tumor site, size, and microscopic characteristics significantly impact prognosis. Female patients generally exhibit better outcomes than males. Distal lesions tend to have better outcomes compared to proximal ones.&#x000a0;Presentation at an earlier age has better outcomes. Tumors larger than 2 cm in diameter, as well as those exhibiting necrosis and vascular invasion, are associated with poorer outcomes. 5-year overall survival rates typically range from 60% to 75%.<xref ref-type="bibr" rid="article-449.r18">[18]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-449.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications associated with epithelioid sarcoma are primarily categorized into those related to the primary disease, treatment-related secondary effects, and those caused by distant metastases. Localized lesion growth can damage surrounding tissues, nerves, blood vessels, and bones, leading to the destruction of the skin, underlying soft tissues, and skeletal structures. Metastases to lymph nodes, lungs, and skin can manifest with local symptoms. Furthermore, depending on the location of the initial tumor, surgical resection and radiation may result in complications.</p>
      </sec>
      <sec id="article-449.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Epithelioid sarcoma is a type of slow-growing soft tissue tumor that is frequently found in the upper extremities, predominantly affecting young men. This condition may present asymptomatically; therefore, patients should be encouraged to have any growths evaluated by a medical professional. Upon diagnosis confirmation, patients should receive counseling on available treatment options, including risks and benefits associated with each. They should also be educated on common posttreatment complications and concerning symptoms and instructed to report any concerning symptoms to their clinician promptly. Clinicians should discuss prognosis expectations and emphasize the necessity of long-term surveillance due to the potential for recurrent tumors, which can arise many years after initial treatment. Although preventive measures to lower the risk of developing this cancer are currently unknown, patients should be advised on the criticality of regular monitoring and adherence to scheduled follow-up appointments for imaging studies.</p>
      </sec>
      <sec id="article-449.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional healthcare team is crucial for improving health outcomes for patients with epithelioid sarcoma, which is a rare and aggressive type of sarcoma. The evaluating physician must maintain a high level of suspicion to ensure timely and accurate diagnosis, which includes obtaining appropriate imaging studies and biopsies. Treating these patients is complex and requires collaboration among surgeons, radiation oncologists, medical oncologists, physical therapists, radiologists, and various supportive departments. Effective care coordination necessitates these healthcare professionals to communicate and discuss cases in interprofessional settings, thereby facilitating joint decisions that enhance patient outcomes. Emphasizing patient-centered care principles ensures that decisions prioritize the patient's quality of life and functionality, thereby improving overall patient safety and team performance.</p>
      </sec>
      <sec id="article-449.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=449&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=449">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/epithelioid-sarcoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=449">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/449/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=449">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-449.s15">
        <fig id="article-449.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Epithelioid Sarcoma, Proximal-Type. The image highlights the proximal-type variant of epithelioid sarcoma, with a close-up insert highlighting rhabdoid cells characterized by prominent nucleoli. Contributed by G Williams, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Epithelioid__Sarcoma__Composite" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-449.s16">
        <title>References</title>
        <ref id="article-449.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Enzinger</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Epitheloid sarcoma. A sarcoma simulating a granuloma or a carcinoma.</article-title>
            <source>Cancer</source>
            <year>1970</year>
            <month>Nov</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>1029</fpage>
            <page-range>1029-41</page-range>
            <pub-id pub-id-type="pmid">5476785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Visscher</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>van Ginkel</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Wobbes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Veth</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Ten Heuvel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Suurmeijer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Hoekstra</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Epithelioid sarcoma: Still an only surgically curable disease.</article-title>
            <source>Cancer</source>
            <year>2006</year>
            <month>Aug</month>
            <day>01</day>
            <volume>107</volume>
            <issue>3</issue>
            <fpage>606</fpage>
            <page-range>606-12</page-range>
            <pub-id pub-id-type="pmid">16804932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hollmann</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Hornick</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>INI1-deficient tumors: diagnostic features and molecular genetics.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>35</volume>
            <issue>10</issue>
            <fpage>e47</fpage>
            <page-range>e47-63</page-range>
            <pub-id pub-id-type="pmid">21934399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Modena</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lualdi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Facchinetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Galli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Pilotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sozzi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.</article-title>
            <source>Cancer Res</source>
            <year>2005</year>
            <month>May</month>
            <day>15</day>
            <volume>65</volume>
            <issue>10</issue>
            <fpage>4012</fpage>
            <page-range>4012-9</page-range>
            <pub-id pub-id-type="pmid">15899790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fisher</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Epithelioid sarcoma of Enzinger.</article-title>
            <source>Adv Anat Pathol</source>
            <year>2006</year>
            <month>May</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>114</fpage>
            <page-range>114-21</page-range>
            <pub-id pub-id-type="pmid">16778474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chase</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Enzinger</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment.</article-title>
            <source>Am J Surg Pathol</source>
            <year>1985</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>241</fpage>
            <page-range>241-63</page-range>
            <pub-id pub-id-type="pmid">4014539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guillou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Coindre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Krausz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>"Proximal-type" epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series.</article-title>
            <source>Am J Surg Pathol</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>130</fpage>
            <page-range>130-46</page-range>
            <pub-id pub-id-type="pmid">9042279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miettinen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sarlomo-Rikala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abdullaev</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Pack</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Fetsch</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>ERG expression in epithelioid sarcoma: a diagnostic pitfall.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>1580</fpage>
            <page-range>1580-5</page-range>
            <pub-id pub-id-type="pmid">23774169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasegawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsuno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shimoda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Umeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yokoyama</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hirohashi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Proximal-type epithelioid sarcoma: a clinicopathologic study of 20 cases.</article-title>
            <source>Mod Pathol</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>655</fpage>
            <page-range>655-63</page-range>
            <pub-id pub-id-type="pmid">11454997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stockman</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Hornick</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Deavers</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Lev</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>ERG and FLI1 protein expression in epithelioid sarcoma.</article-title>
            <source>Mod Pathol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>496</fpage>
            <page-range>496-501</page-range>
            <pub-id pub-id-type="pmid">24072183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sobanko</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nigra</surname>
                <given-names>TP</given-names>
              </name>
            </person-group>
            <article-title>Epithelioid sarcoma: a review and update.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2009</year>
            <month>May</month>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>49</fpage>
            <page-range>49-54</page-range>
            <pub-id pub-id-type="pmid">20729965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noujaim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thway</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bajwa</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bajwa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maki</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy.</article-title>
            <source>Front Oncol</source>
            <year>2015</year>
            <volume>5</volume>
            <fpage>186</fpage>
            <pub-id pub-id-type="pmid">26347853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Callister</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Ballo</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Pisters</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Feig</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Zagars</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Epithelioid sarcoma: results of conservative surgery and radiotherapy.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2001</year>
            <month>Oct</month>
            <day>01</day>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>384</fpage>
            <page-range>384-91</page-range>
            <pub-id pub-id-type="pmid">11567812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Straining</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eighmy</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Tazemetostat: EZH2 Inhibitor.</article-title>
            <source>J Adv Pract Oncol</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>158</fpage>
            <page-range>158-163</page-range>
            <pub-id pub-id-type="pmid">35369397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czarnecka</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Sobczuk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kostrzanowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Spalek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chojnacka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Szumera-Cieckiewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rutkowski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Epithelioid Sarcoma-From Genetics to Clinical Practice.</article-title>
            <source>Cancers (Basel)</source>
            <year>2020</year>
            <month>Jul</month>
            <day>29</day>
            <volume>12</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">32751241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>den Bakker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Flood</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kliffen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>CD31 staining in epithelioid sarcoma.</article-title>
            <source>Virchows Arch</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>443</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-7</page-range>
            <pub-id pub-id-type="pmid">12743818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kohashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hotokebuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Taguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwamoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Oda</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor.</article-title>
            <source>Hum Pathol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>225</fpage>
            <page-range>225-30</page-range>
            <pub-id pub-id-type="pmid">25479928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-449.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jawad</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Extein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Scully</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>467</volume>
            <issue>11</issue>
            <fpage>2939</fpage>
            <page-range>2939-48</page-range>
            <pub-id pub-id-type="pmid">19224301</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
